The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhaled Liposomal Antimicrobial Delivery in Lung Infections
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a chronic Pseudomonas rat model, liposomal bismuth ethanedithiol lowered bacterial counts.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [204]
In the citing paper
“Reviews support inhaled, NP enabled antibiotic strategies for difficult lung infections [203,204,205].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [204]
In the citing paper
“In the airway, liposomal formulations improve residence time, reduce epithelial toxicity, and enhance penetration of mucus-rich and matrix-rich regions.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Weiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J., Edwards, J. R., & Sievert, D. M. (2016) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2016.174 · Cited by 1,313
Patil, J., Devi, V., Devi, K., & Sarasija, S. (2015) · Lung India · doi:10.4103/0970-2113.159559 · Cited by 98
Research works printed but not linked: 67
- Bassetti M, Russo A, Carnelutti A, La Rosa A, Righi E. Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opin Drug Saf. 2018;17(7):669–80. · doi:10.1080/14740338.2018.1488962
- Rello J, Parisella FR, Perez A. Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. Expert Rev Clin Pharmacol. 2019;12(7):635–42. · DOI
- Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis. 1992;15(4):654–67. · DOI
- Alipour M, Suntres ZE. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa. Therap Deliv. 2014;5(4):409–27. · DOI
- Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanosc Res Lett. 2013;8(1):102. · DOI · Paper page
- Bos AC, Passe KM, Mouton JW, Janssens HM, Tiddens HA. The fate of inhaled antibiotics after deposition in cystic fibrosis: how to get drug to the bug? J Cyst Fibrosis. 2017;16(1):13–23. · doi:10.1016/j.jcf.2016.10.001
- Sweeney DA, Kalil AC. Why Don't We have more inhaled antibiotics to treat ventilator-associated pneumonia? Clin Microbial Infection. 2019;20:20.
- Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM. Inhaled antibiotics: dry or wet? Eur Respire J. 2014;44(5):1308–18. · doi:10.1183/09031936.00090314
- Bos AC, van Holsbeke C, de Backer JW, van Westreenen M, Janssens HM, Vos WG, Tiddens HA. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough? PLoS One. 2015;10(3):e0118454. · DOI
- Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One. 2009;4(5):e5724. · DOI
- Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 2018;9:155. · DOI · Paper page
- Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016;6(1):35. · doi:10.1186/s13613-016-0140-x
- Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68(9):818–25. · DOI · Paper page
- Waters V, Ratjen F. Inhaled liposomal amikacin. Expert review of respiratory medicine. 2014;8(4):401–9. · DOI
- Peghin M, Monforte V, Martin-Gomez MT, Ruiz-Camps I, Berastegui C, Saez B, Riera J, Ussetti P, Sole J, Gavalda J, et al. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation. Transpl Int. 2016;29(1):51–62. · DOI
- Peghin M, Monforte V, Martin-Gomez MT, Ruiz-Camps I, Berastegui C, Saez B, Riera J, Sole J, Gavalda J, Roman A. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients. Transplant Infect Dis. 2016;18(1):70–8. · DOI
- Rudokas M, Najlah M, Alhnan MA, Elhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Principles Pract. 2016;25(Suppl 2):60–72. · DOI · Paper page
- Najlah M, Parveen I, Alhnan MA, Ahmed W, Faheem A, Phoenix DA, Taylor KM, Elhissi A. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int J Pharm. 2014;461(1–2):234–41. · doi:10.1016/j.ijpharm.2013.11.022
- Lehofer B, Bloder F, Jain PP, Marsh LM, Leitinger G, Olschewski H, Leber R, Olschewski A, Prassl R. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. Eur J Pharm Biopharm. 2014;88(3):1076–85. · DOI
- Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. · DOI · Paper page
- Ehsan Z, Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol. 2015;10(12):1901–12. · DOI
- Paredes Aller S, Quittner AL, Salathe MA, Schmid A. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis—experiences from recent clinical trials. Expert Rev Respir Med. 2018;12(9):769–82. · DOI
- Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2018;3:CD001021.
- Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2019;7(10):855–69. · DOI
- Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Canton R, Torres A, Dimakou K, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:3. · DOI · Paper page
- Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for gram-negative respiratory infections. Clin Microbiol Rev. 2016;29(3):581–632. · DOI
- Rello J, Sole-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera J, Palmer LB, Pereira JM, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbial Infect. 2017;23(9):629–39. · DOI · Paper page
- Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11(3):425–34. · DOI · Paper page
- Suhling H, Rademacher J, Greer M, Haverich A, Warnecke G, Gottlieb J, Welte T. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respire J. 2013;42(2):542–4. · doi:10.1183/09031936.00201012
- Ruiz I, Gavalda J, Monforte V, Len O, Roman A, Bravo C, Ferrer A, Tenorio L, Roman F, Maestre J, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6(1):178–82. · doi:10.1111/j.1600-6143.2005.01145.x
- Traini D, Young PM. Drug delivery for tuberculosis: is inhaled therapy the key to success? Therap Deliv. 2017;8(10):819–21. · DOI
- Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respire Crit Care Med. 2018;198(12):1559–69. · DOI · Paper page
- Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics. 2016;8:1. · DOI · Paper page
- Hamblin KA, Armstrong SJ, Barnes KB, Davies C, Laws T, Blanchard JD, Harding SV, Atkins HS. Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague. Front Microbiol. 2017;8:91. · DOI
- Burton AJ, Giguere S, Arnold RD. Pharmacokinetics, pulmonary disposition and tolerability of liposomal gentamicin and free gentamicin in foals. Equine Vet J. 2015;47(4):467–72. · DOI
- Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother. 2012;56(5):2612–8. · DOI
- Ricci M, Giovagnoli S, Blasi P, Schoubben A, Perioli L, Rossi C. Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int J Pharm. 2006;311(1–2):172–81. · doi:10.1016/j.ijpharm.2005.12.031
- Justo OR, Moraes AM. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv. 2003;10(3):201–7. · DOI
- He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013;42(6):559–64. · doi:10.1016/j.ijantimicag.2013.07.009
- Chimote G, Banerjee R. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J Biomed Mater Res B Appl Biomater. 2010;94(1):1–10. · DOI
- Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother. 2009;53(9):3847–54. · DOI
- Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61(4):859–68. · DOI · Paper page
- Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulmon Drug Deliv. 2009;22(2):131–8. · DOI
- Li Z, Zhang Y, Wurtz W, Lee JK, Malinin VS, Durwas-Krishnan S, Meers P, Perkins WR. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulmon Drug Deliv. 2008;21(3):245–54. · DOI
- Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibrosis. 2018;17(2):153–78. · DOI · Paper page
- Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16(4):749–67. · DOI · Paper page
- Bilton D, Pressler T, Fajac I, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Sole A, Quittner AL, et al. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibrosis. 2019;20:20.
- Halwani M, Mugabe C, Azghani AO, Lafrenie RM, Kumar A, Omri A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother. 2007;60(4):760–9. · DOI
- Marier JF, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother. 2003;52(2):247–52. · DOI
- Gungor N, Knaapen AM, Munnia A, Peluso M, Haenen GR, Chiu RK, Godschalk RW, van Schooten FJ. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis. 2010;25(2):149–54. · DOI · Paper page
- Forier K, Messiaen AS, Raemdonck K, Nelis H, De Smedt S, Demeester J, Coenye T, Braeckmans K. Probing the size limit for nanomedicine penetration into Burkholderia multivorans and Pseudomonas aeruginosa biofilms. J Control Release. 2014;195:21–8. · DOI
- Waters V, Smyth A. Cystic fibrosis microbiology: advances in antimicrobial therapy. J Cyst Fibros. 2015;14(5):551–60. · DOI
- Banaschewski B, Hofmann T: Inhaled Antibiotics for Mycobacterial Lung Disease. Pharmaceutics 2019, 11(7). · DOI
- Khatib I, Khanal D, Ruan J, Cipolla D, Dayton F, Blanchard JD, Chan HK. Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. Int J Pharm. 2019;566:641–51. · DOI
- Blanchard JD, Elias V, Cipolla D, Gonda I, Bermudez LE. Effective treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus species infections in macrophages, biofilm, and mice by using liposomal ciprofloxacin. Antimicrob Agents Chemother. 2018;62:10. · doi:10.1128/aac.00440-18
- Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I. investigators O-: Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68(9):812–7. · DOI · Paper page
- Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008;21(1):71–6. · doi:10.1089/jamp.2007.0652
- Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–65. · DOI · Paper page
- Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med. 2019;7(3):213–26. · DOI · Paper page
- Le J, Schiller DS. Aerosolized delivery of antifungal agents. Curr Fungal Infect Rep. 2010;4(2):96–102. · DOI
- Borro JM, Sole A, de la Torre M, Pastor A, Fernandez R, Saura A, Delgado M, Monte E, Gonzalez D. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transpl Proc. 2008;40(9):3090–3. · DOI
- Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D, Len O, Puigfel Y, Ruiz I, Pahissa A. Efficacy of nebulized liposomal amphotericin B in treatment of experimental Pulmonary aspergillosis. Antimicrob Agents Chemother. 2005;49(7):3028–30. · DOI
- Monforte V, Ussetti P, Lopez R, Gavalda J, Bravo C, de Pablo A, Pou L, Pahissa A, Morell F, Roman A. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28(2):170–5. · DOI
- Monforte V, Ussetti P, Gavalda J, Bravo C, Laporta R, Len O, Garcia-Gallo CL, Tenorio L, Sole J, Roman A. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant. 2010;29(5):523–30. · DOI
- Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, et al. Aerosolized liposomal amphotericin B for the prevention of invasive Pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401–8. · DOI · Paper page
- Godet C, Cateau E, Rammaert B, Grosset M, Le Moal G, Beraud G, Martellosio JP, Iriart X, Cadranel J, Roblot F. Nebulized liposomal amphotericin B for treatment of pulmonary infection caused by Hormographiella aspergillata: case report and literature review. Mycopathologia. 2017;182(7–8):709–13. · DOI
- Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Deliv. 2009;22(3):213–27. · DOI
Cited by
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Arunachalam, K., Pandurangan, P., Shi, C., & Lagoa, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020310 · Cited by 48
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Bassetti, M., Vena, A., Russo, A., & Peghin, M.
- ORCID
- Bassetti, Matteo
- Venue
- Drugs
- Published
- 2020-07-20
- Volume
- 80
- Issue
- 13
- Pages
- 1309-1318
- ISSN
- 0012-6667
- 1179-1950
- Cited by
- 154
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled Liposomal Antimicrobial Delivery in Lung Infections. https://app.cochat.ai/papers/10.1007/s40265-020-01359-z
- The paper
- Bassetti, M., Vena, A., Russo, A., & Peghin, M. (2020). Inhaled Liposomal Antimicrobial Delivery in Lung Infections. Drugs. https://doi.org/10.1007/s40265-020-01359-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.